Loading clinical trials...
Loading clinical trials...
A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Conditions
Interventions
TGR-1202
nab-paclitaxel + gemcitabine
+2 more
Locations
1
United States
TG Therapeutics Trial Site
Nashville, Tennessee, United States
Start Date
September 11, 2015
Primary Completion Date
August 1, 2018
Completion Date
August 1, 2018
Last Updated
October 2, 2019
NCT07446322
NCT07541924
NCT07542041
NCT07283705
NCT07438106
NCT04693377
Lead Sponsor
TG Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions